Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
종목 코드 BVS
회사 이름Bioventus Inc
상장일Feb 11, 2021
CEOMr. Robert E. Claypoole
직원 수930
유형Ordinary Share
회계 연도 종료Feb 11
주소4721 Emperor Boulevard, Suite 100
도시DURHAM
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호27703
전화19194746700
웹사이트https://www.bioventus.com/
종목 코드 BVS
상장일Feb 11, 2021
CEOMr. Robert E. Claypoole
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음